NEW YORK (
) hit a new 52-week low Thursday as it is currently trading at $25.46, below its previous 52-week low of $25.60 with 85,086 shares traded as of 12 p.m. ET. Average volume has been 336,500 shares over the past 30 days.
Par Pharmaceutical Companies has a market cap of $1 billion and is part of the
industry. Shares are down 28% year to date as of the close of trading on Wednesday.
Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. engages in developing, licensing, manufacturing, marketing, and distributing generic and branded drugs in the United States.
- Practice your PRX trading strategies and win cash in our stock game.
TheStreet Ratings rates Par Pharmaceutical Companies as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full
or get investment ideas from our